The Value of Phosphohistone H3 As a Cell Proliferation Marker in Oral Squamous Cell Carcinoma. A Comparative Study with Ki-67 and the Mitotic Activity Index

Overview

Journal Med Oral Patol Oral Cir Bucal

Specialty Dentistry

Date 2022 Aug 17

PMID 35975799

Authors

N Tancredi-Cueto

G Vigil-Bastitta

R Bologna-Molina

V Beovide-Cortegoso

Affiliations

Soon will be listed here.

Abstract

Background: The Phosphohistone H3 (PHH3) antibody is recognized as a biomarker of cell proliferation, specific for cells in mitosis, of prognostic value in different malignant neoplasms, however it has been poorly studied in oral squamous cell carcinoma (OSCC). The main objective of this study was to evaluate the immunoexpression of the PHH3 in the OSCC, through the correlation with the immunoexpression of Ki-67, the mitotic activity index (MAI), histological grading, clinical-morphological parameters and the rate of survival.

Material And Methods: The study sample consisted of 62 cases of OSCC diagnosed in the Pathological Anatomy Laboratory of the Faculty of Dentistry, University of the Republic (Uruguay). In each of them, an immunohistochemical technique was performed for Ki-67 and PHH3 (serine 10) antibodies. Image J software was used for the MAI and biomarker quantification, defining the percentage of positivity and mitotic figures per 1000 tumor cells.

Results: a significant association was obtained between the expression of PHH3 (p 0.016) and MAI (p 0.031) with survival time. However, no similar relationship was found with Ki-67 (p 0.295). Although it was confirmed a statistical association between histological grade and Ki-67 immunoexpression (p 0.004), PHH3 did not show a similar relationship (p 0.564).

Conclusions: It was confirmed the role of the PHH3 antibody as a biomarker of mitotic figures in OSCC and as a potential marker of cell proliferation. It is noteworthy that this is one of the first works that evaluates a possible relationship between the expression of this antibody and survival in OSCC.

Citing Articles

Mitosis - predicting primary tumour and metastatic lymph node behaviour and beyond in OSCC - A pilot study.

Makarla S, Bavle R, Topajiche S J Oral Maxillofac Pathol. 2025; 28(4):602-611.

PMID: 39949704 PMC: 11819642. DOI: 10.4103/jomfp.jomfp_292_24.

Hippo effector, Yorkie, is a tumor suppressor in select squamous epithelia.

Bhattacharya R, Kumari J, Banerjee S, Tripathi J, Parihar S, Mohan N Proc Natl Acad Sci U S A. 2024; 121(39):e2319666121.

PMID: 39288176 PMC: 11441523. DOI: 10.1073/pnas.2319666121.

Prognostic importance of mitosis quantification and PHH3 expression in oral epithelial dysplasia.

Sathyamoorthy H, Mahmood H, Zubir A, Hankinson P, Khurram S Virchows Arch. 2023; 484(1):47-59.

PMID: 37882821 PMC: 10791886. DOI: 10.1007/s00428-023-03668-6.

References

Almangush A, Makitie A, Triantafyllou A, de Bree R, Strojan P, Rinaldo A . Staging and grading of oral squamous cell carcinoma: An update. Oral Oncol. 2020; 107:104799. DOI: 10.1016/j.oraloncology.2020.104799. View

Speight P, Farthing P . The pathology of oral cancer. Br Dent J. 2018; 225(9):841-847. DOI: 10.1038/sj.bdj.2018.926. View

Junior H, Leao P, Melo V, Caixeta A, Souza P, de Aguiar M . Cell proliferation is associated with intensity of tumor budding in oral squamous cell carcinoma. J Oral Pathol Med. 2017; 47(2):128-135. DOI: 10.1111/jop.12653. View

Elmaci I, Altinoz M, Sari R, Bolukbasi F . Phosphorylated Histone H3 (PHH3) as a Novel Cell Proliferation Marker and Prognosticator for Meningeal Tumors: A Short Review. Appl Immunohistochem Mol Morphol. 2017; 26(9):627-631. DOI: 10.1097/PAI.0000000000000499. View

Lai C, Yeong J, Tan A, Ong C, Lee B, Lim J . Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence. Breast Cancer Res Treat. 2019; 178(2):295-305. DOI: 10.1007/s10549-019-05396-5. View

Lea D, Gudlaugsson E, Skaland I, Lillesand M, Soreide K, Soreide J . Digital Image Analysis of the Proliferation Markers Ki67 and Phosphohistone H3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Accuracy of Grading Compared With Routine Manual Hot Spot Evaluation of the Ki67 Index. Appl Immunohistochem Mol Morphol. 2021; 29(7):499-505. PMC: 8354564. DOI: 10.1097/PAI.0000000000000934. View

Chitra N, Boaz K, N S, Lewis A, K S S . Pattern-Corrected Mitotic Activity Index (PMAI): A Novel Prognosticator of Oral Squamous Cell Carcinoma. Turk Patoloji Derg. 2019; 36(1):31-38. PMC: 10512675. DOI: 10.5146/tjpath.2019.01465. View

Takkem A, Barakat C, Zakaraia S, Zaid K, Najmeh J, Ayoub M . Ki-67 Prognostic Value in Different Histological Grades of Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma. Asian Pac J Cancer Prev. 2018; 19(11):3279-3286. PMC: 6318382. DOI: 10.31557/APJCP.2018.19.11.3279. View

Dias E, Oliveira N, Serra-Campos A, Fausto da Silva A, Esmeraldo da Silva L, Cunha K . A novel evaluation method for Ki-67 immunostaining in paraffin-embedded tissues. Virchows Arch. 2021; 479(1):121-131. DOI: 10.1007/s00428-020-03010-4. View

10.

Oliveira M, Wagner V, Filho M, Carrard V, Hugo F, Martins M . A 10-year analysis of the oral squamous cell carcinoma profile in patients from public health centers in Uruguay. Braz Oral Res. 2015; 29. DOI: 10.1590/1807-3107BOR-2015.vol29.0075. View

11.

Gadbail A, Sarode S, Chaudhary M, Gondivkar S, Tekade S, Yuwanati M . Ki67 Labelling Index predicts clinical outcome and survival in oral squamous cell carcinoma. J Appl Oral Sci. 2021; 29:e20200751. PMC: 7934280. DOI: 10.1590/1678-7757-2020-0751. View

12.

Yang H, Jin X, Dan H, Chen Q . Histone modifications in oral squamous cell carcinoma and oral potentially malignant disorders. Oral Dis. 2019; 26(4):719-732. DOI: 10.1111/odi.13115. View

13.

Brockton N, Lohavanichbutr P, Enwere E, Upton M, Kornaga E, Nakoneshny S . Impact of tumoral carbonic anhydrase IX and Ki-67 expression on survival in oral squamous cell carcinoma patients. Oncol Lett. 2017; 14(5):5434-5442. PMC: 5652251. DOI: 10.3892/ol.2017.6829. View

14.

Khieu M, Broadwater D, Aden J, Coviello J, Lynch D, Hall J . The Utility of Phosphohistone H3 (PHH3) in Follicular Lymphoma Grading: A Comparative Study With Ki-67 and H&E Mitotic Count. Am J Clin Pathol. 2019; 151(6):542-550. DOI: 10.1093/ajcp/aqz003. View

15.

Ohashi R, Namimatsu S, Sakatani T, Naito Z, Takei H, Shimizu A . Prognostic utility of atypical mitoses in patients with breast cancer: A comparative study with Ki67 and phosphohistone H3. J Surg Oncol. 2018; 118(3):557-567. DOI: 10.1002/jso.25152. View

16.

Blatt S, Kruger M, Ziebart T, Sagheb K, Schiegnitz E, Goetze E . Biomarkers in diagnosis and therapy of oral squamous cell carcinoma: A review of the literature. J Craniomaxillofac Surg. 2017; 45(5):722-730. DOI: 10.1016/j.jcms.2017.01.033. View

17.

Kim J, Jeong H, Chung T, Kim M, Lee J, Jung W . The value of phosphohistone H3 as a proliferation marker for evaluating invasive breast cancers: A comparative study with Ki67. Oncotarget. 2017; 8(39):65064-65076. PMC: 5630312. DOI: 10.18632/oncotarget.17775. View

18.

Jing Y, Zhou Q, Zhu H, Zhang Y, Song Y, Zhang X . Ki-67 is an independent prognostic marker for the recurrence and relapse of oral squamous cell carcinoma. Oncol Lett. 2019; 17(1):974-980. PMC: 6312995. DOI: 10.3892/ol.2018.9647. View

19.

van Steenhoven J, Kuijer A, Kornegoor R, van Leeuwen G, van Gorp J, van Dalen T . Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer. Histopathology. 2020; 77(4):579-587. PMC: 7539961. DOI: 10.1111/his.14185. View

20.

Lopes V, Souza de Jesus A, de Souza L, Miyahara L, Guimaraes D, Pontes H . Ki-67 protein predicts survival in oral squamous carcinoma cells: an immunohistochemical study. Braz Oral Res. 2017; 31:e66. DOI: 10.1590/1807-3107BOR-2017.vol31.0066. View